Troy Wilson

Troy Wilson has extensive experience in the biopharmaceutical industry, with a focus on developing innovative treatments for cancer and other serious diseases. Troy has held various executive roles in multiple companies, including President and Chief Executive Officer at Kura Oncology, Inc. since 2014, Executive Chairman of the Board of Directors at Wellspring Biosciences since 2012, and Executive Chairman of the Board of Directors at Avidity Biosciences, Inc. also since 2012. Prior to that, they co-founded and served as President, CEO, and Co-Founder at Wellspring Biosciences and Avidity Biosciences. Troy was also a Member of the Board of Directors at Puma Biotechnology and held the position of President, CEO, and Co-Founder at Intellikine. Before these roles, they served as President and Co-Founder at Wildcat Discovery Technologies and Chief Business Officer and Founder at Ambrx. Troy Wilson started their career at GNF as Vice President, Business Development, and General Counsel.

Troy Wilson holds a J.D. degree from the New York University School of Law and a Ph.D. in Biorganic Chemistry from the University of California, Berkeley.